# Amylyx Pharmaceuticals, Inc.: financial statements, quarterly

AMLX · Nasdaq · CIK 1658551 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amlx.md) · [Financials](/companies/amlx/financials.md) · [Filings](/companies/amlx/filings.md) · [Insiders](/companies/amlx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amlx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [103](/filings/0000950170-24-122833.md) | [108 d](/filings/0000950170-25-031309.md) | [88.6](/filings/0000950170-25-066363.md) | [(1.0)](/filings/0001193125-25-174948.md) | [0.4](/filings/0001193125-25-268059.md) | [(0.7) d](/filings/0001193125-26-086645.md) | [0.0](/filings/0000950170-25-066363.md) | [0.0](/filings/0001193125-25-174948.md) | [0.0](/filings/0001193125-25-268059.md) | [0.0 d](/filings/0001193125-26-086645.md) | not reported | not reported |
| Cost of revenue | $m | [5.2](/filings/0000950170-24-122833.md) | [9.4 d](/filings/0000950170-25-031309.md) | [5.9](/filings/0000950170-25-066363.md) | [0.0](/filings/0001193125-25-174948.md) | [0.0](/filings/0001193125-25-268059.md) | [0.0 d](/filings/0001193125-26-086645.md) | [0.0](/filings/0000950170-25-066363.md) | [0.0](/filings/0001193125-25-174948.md) | [0.0](/filings/0001193125-25-268059.md) | [0.0 d](/filings/0001193125-26-086645.md) | not reported | not reported |
| Research and development | $m | [30.0](/filings/0000950170-24-122833.md) | [44.9 d](/filings/0000950170-25-031309.md) | [36.6](/filings/0000950170-25-066363.md) | [23.3](/filings/0001193125-25-174948.md) | [21.2](/filings/0001193125-25-268059.md) | [22.9 d](/filings/0001193125-26-086645.md) | [22.1](/filings/0001193125-26-210292.md) | [27.2](/filings/0001193125-26-336682.md) | [19.9](/filings/0001193125-25-268059.md) | [21.2 d](/filings/0001193125-26-086645.md) | [27.6](/filings/0001193125-26-210292.md) | [23.8](/filings/0001193125-26-336682.md) |
| Selling, general and administrative | $m | [48.7](/filings/0000950170-24-122833.md) | [52.2 d](/filings/0000950170-25-031309.md) | [57.8](/filings/0000950170-25-066363.md) | [21.6](/filings/0001193125-25-174948.md) | [17.8](/filings/0001193125-25-268059.md) | [17.1 d](/filings/0001193125-26-086645.md) | [15.7](/filings/0001193125-26-210292.md) | [15.6](/filings/0001193125-26-336682.md) | [16.2](/filings/0001193125-25-268059.md) | [15.4 d](/filings/0001193125-26-086645.md) | [16.2](/filings/0001193125-26-210292.md) | [21.9](/filings/0001193125-26-336682.md) |
| Operating income | $m | [18.7](/filings/0000950170-24-122833.md) | [1.9 d](/filings/0000950170-25-031309.md) | [(122)](/filings/0000950170-25-066363.md) | [(76.3)](/filings/0001193125-25-174948.md) | [(75.7)](/filings/0001193125-25-268059.md) | [(40.7) d](/filings/0001193125-26-086645.md) | [(37.8)](/filings/0001193125-26-210292.md) | [(42.9)](/filings/0001193125-26-336682.md) | [(36.0)](/filings/0001193125-25-268059.md) | [(36.6) d](/filings/0001193125-26-086645.md) | [(43.8)](/filings/0001193125-26-210292.md) | [(45.7)](/filings/0001193125-26-336682.md) |
| Income tax | $m | [1.5](/filings/0000950170-24-122833.md) | [1.7 d](/filings/0000950170-25-031309.md) | [0.2](/filings/0000950170-25-066363.md) | [0.0](/filings/0001193125-25-174948.md) | [0.0](/filings/0001193125-25-268059.md) | [(0.6) d](/filings/0001193125-26-086645.md) | [0.0](/filings/0000950170-25-066363.md) | [0.0](/filings/0001193125-25-174948.md) | [0.0](/filings/0001193125-25-268059.md) | [0.0 d](/filings/0001193125-26-086645.md) | not reported | not reported |
| Net income | $m | [20.9](/filings/0000950170-24-122833.md) | [4.7 d](/filings/0000950170-25-031309.md) | [(119)](/filings/0001193125-25-268059.md) | [(72.7)](/filings/0001193125-25-268059.md) | [(72.7)](/filings/0001193125-25-268059.md) | [(37.5) d](/filings/0001193125-26-086645.md) | [(35.9)](/filings/0001193125-26-336682.md) | [(41.4)](/filings/0001193125-26-336682.md) | [(34.4)](/filings/0001193125-25-268059.md) | [(33.0) d](/filings/0001193125-26-086645.md) | [(41.3)](/filings/0001193125-26-336682.md) | [(43.4)](/filings/0001193125-26-336682.md) |
| Diluted EPS | $ per share | [0.30](/filings/0000950170-24-122833.md) | not reported | [(1.75)](/filings/0000950170-25-066363.md) | [(1.07)](/filings/0001193125-25-174948.md) | [(1.07)](/filings/0001193125-25-268059.md) | not reported | [(0.42)](/filings/0001193125-26-210292.md) | [(0.46)](/filings/0001193125-26-336682.md) | [(0.37)](/filings/0001193125-25-268059.md) | not reported | [(0.37)](/filings/0001193125-26-210292.md) | [(0.39)](/filings/0001193125-26-336682.md) |
| Basic EPS | $ per share | [0.31](/filings/0000950170-24-122833.md) | not reported | [(1.75)](/filings/0000950170-25-066363.md) | [(1.07)](/filings/0001193125-25-174948.md) | [(1.07)](/filings/0001193125-25-268059.md) | not reported | [(0.42)](/filings/0001193125-26-210292.md) | [(0.46)](/filings/0001193125-26-336682.md) | [(0.37)](/filings/0001193125-25-268059.md) | not reported | [(0.37)](/filings/0001193125-26-210292.md) | [(0.39)](/filings/0001193125-26-336682.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [135](/filings/0000950170-24-122833.md) | [170](/filings/0000950170-25-031309.md) | [171](/filings/0000950170-25-066363.md) | [75.0](/filings/0001193125-25-174948.md) | [71.8](/filings/0001193125-25-268059.md) | [77.4](/filings/0001193125-26-086645.md) | [59.8](/filings/0001193125-26-210292.md) | [58.1](/filings/0001193125-26-336682.md) | [225](/filings/0001193125-25-268059.md) | [227](/filings/0001193125-26-336682.md) | [229](/filings/0001193125-26-210292.md) | [49.3](/filings/0001193125-26-336682.md) |
| Current assets | $m | [434](/filings/0000950170-23-061516.md) | [465](/filings/0000950170-25-031309.md) | [411](/filings/0000950170-24-056269.md) | [327](/filings/0000950170-24-093311.md) | [245](/filings/0000950170-24-122833.md) | [189](/filings/0001193125-26-086645.md) | [216](/filings/0000950170-25-066363.md) | [187](/filings/0001193125-25-174948.md) | [353](/filings/0001193125-25-268059.md) | [324](/filings/0001193125-26-336682.md) | [285](/filings/0001193125-26-210292.md) | [256](/filings/0001193125-26-336682.md) |
| Total assets | $m | [467](/filings/0000950170-23-061516.md) | [517](/filings/0000950170-25-031309.md) | [417](/filings/0000950170-24-056269.md) | [332](/filings/0000950170-24-093311.md) | [251](/filings/0000950170-24-122833.md) | [194](/filings/0001193125-26-086645.md) | [220](/filings/0000950170-25-066363.md) | [195](/filings/0001193125-25-174948.md) | [363](/filings/0001193125-25-268059.md) | [333](/filings/0001193125-26-336682.md) | [294](/filings/0001193125-26-210292.md) | [265](/filings/0001193125-26-336682.md) |
| Current liabilities | $m | [45.6](/filings/0000950170-23-061516.md) | [82.0](/filings/0000950170-25-031309.md) | [91.6](/filings/0000950170-24-056269.md) | [70.1](/filings/0000950170-24-093311.md) | [53.9](/filings/0000950170-24-122833.md) | [28.4](/filings/0001193125-26-086645.md) | [17.9](/filings/0000950170-25-066363.md) | [21.4](/filings/0001193125-25-174948.md) | [25.8](/filings/0001193125-25-268059.md) | [22.7](/filings/0001193125-26-336682.md) | [16.0](/filings/0001193125-26-210292.md) | [21.2](/filings/0001193125-26-336682.md) |
| Total liabilities | $m | [48.2](/filings/0000950170-23-061516.md) | [84.0](/filings/0000950170-25-031309.md) | [93.0](/filings/0000950170-24-056269.md) | [70.9](/filings/0000950170-24-093311.md) | [54.5](/filings/0000950170-24-122833.md) | [28.9](/filings/0001193125-26-086645.md) | [18.3](/filings/0000950170-25-066363.md) | [26.7](/filings/0001193125-25-174948.md) | [30.7](/filings/0001193125-25-268059.md) | [27.4](/filings/0001193125-26-336682.md) | [20.4](/filings/0001193125-26-210292.md) | [25.4](/filings/0001193125-26-336682.md) |
| Shareholders' equity | $m | [418](/filings/0000950170-24-122833.md) | [433](/filings/0001193125-26-086645.md) | [324](/filings/0001193125-25-268059.md) | [261](/filings/0001193125-25-268059.md) | [196](/filings/0001193125-25-268059.md) | [165](/filings/0001193125-26-336682.md) | [201](/filings/0001193125-26-336682.md) | [168](/filings/0001193125-26-336682.md) | [332](/filings/0001193125-25-268059.md) | [305](/filings/0001193125-26-336682.md) | [273](/filings/0001193125-26-336682.md) | [239](/filings/0001193125-26-336682.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.2) d](/filings/0000950170-24-122833.md) | [13.6 d](/filings/0000950170-25-031309.md) | [(0.5)](/filings/0000950170-25-066363.md) | [(66.6) d](/filings/0001193125-25-174948.md) | [(41.6) d](/filings/0001193125-25-268059.md) | [(59.0) d](/filings/0001193125-26-086645.md) | [(39.8)](/filings/0001193125-26-210292.md) | [(25.2) d](/filings/0001193125-26-336682.md) | [(30.4) d](/filings/0001193125-25-268059.md) | [(27.9) d](/filings/0001193125-26-086645.md) | [(36.9)](/filings/0001193125-26-210292.md) | [(31.4) d](/filings/0001193125-26-336682.md) |
| Capital expenditure | $m | [0.4 d](/filings/0000950170-24-122833.md) | [0.4 d](/filings/0000950170-25-031309.md) | [0.1](/filings/0000950170-25-066363.md) | [0.1 d](/filings/0001193125-25-174948.md) | [(0.0) d](/filings/0001193125-25-268059.md) | [0.0 d](/filings/0001193125-26-086645.md) | [0.0](/filings/0001193125-26-210292.md) | [0.0 d](/filings/0001193125-26-336682.md) | [0.0 d](/filings/0001193125-25-268059.md) | [0.1 d](/filings/0001193125-26-086645.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [58.5](/filings/0000950170-23-061516.md) | [70.9](/filings/0000950170-24-056269.md) | [70.1](/filings/0000950170-24-093311.md) | [69.7](/filings/0000950170-24-122833.md) | [67.9](/filings/0000950170-25-066363.md) | [68.0](/filings/0001193125-25-174948.md) | [68.1](/filings/0001193125-25-268059.md) | [85.7](/filings/0001193125-26-210292.md) | [89.1](/filings/0001193125-26-336682.md) | [93.3](/filings/0001193125-25-268059.md) | [111](/filings/0001193125-26-210292.md) | [111](/filings/0001193125-26-336682.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 111,423,048 at 2026-07-27, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336682.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.